[Reduction of blast-colony forming cell development and bi-potential commitment by neutralizing TGF-beta1 in vitro].
To study the regulation of TGF-beta(1) on the development of hemangioblast, embryonic stem cell-derived blast forming cells (BL-CFC) were used as the model of hemangioblast in vitro. TGF-beta(1) or anti-TGF-beta(1) neutralization antibody was added in the medium of embryoid body (EB) generation for observating influence of TGF-B(1) addition in different culture stages on number of BL-CFC and differentiation of BL-CFC to endothelial and hematopoietic cells. The results showed that antagonizing TGF-beta(1) in the course of EB growth could significantly reduce the number of BL-CFC (P<0.01), and the frequency of Flk-1(+) cells was also decreased consistently. Furthermore, the BL-CFC derived from EB pretreated with TGF-beta(1) demonstrated remarkably elevated hematopoietic and endothelial potential, whereas such bi-potential was impaired in the group with neutralizing antibody. It is concluded that TGF-beta(1), a conventional negative regulator in hematopoiesis and angiogenesis exert positive effects on the development and differentiation capacities of BL-CFC in vitro.
Yao
Hui-Yu
HY
Department of Molecular Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
Liu
Bing
B
Wang
Xiao-Yan
XY
Mao
Ning
N
D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects*; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D053595:Embryonic Stem Cells / Q000166:cytology*; D006410:Hematopoiesis / Q000502:physiology; D051379:Mice; D018919:Neovascularization, Physiologic / Q000502:physiology*; D053773:Transforming Growth Factor beta1 / Q000037:antagonists & inhibitors*
D053773:Transforming Growth Factor beta1